Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Interest Expenses (2016 - 2025)

Historic Interest Expenses for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $948242.0.

  • CorMedix's Interest Expenses rose 937578.69% to $948242.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $974927.0, marking a year-over-year increase of 236748.25%. This contributed to the annual value of $36405.0 for FY2024, which is 614.94% up from last year.
  • According to the latest figures from Q3 2025, CorMedix's Interest Expenses is $948242.0, which was up 937578.69% from $6671.0 recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Interest Expenses peaked at $948242.0 during Q3 2025, and registered a low of $3585.0 during Q2 2022.
  • Over the past 5 years, CorMedix's median Interest Expenses value was $8775.0 (recorded in 2022), while the average stood at $63030.7.
  • Per our database at Business Quant, CorMedix's Interest Expenses tumbled by 3101.28% in 2021 and then soared by 937578.69% in 2025.
  • CorMedix's Interest Expenses (Quarter) stood at $5378.0 in 2021, then surged by 63.16% to $8775.0 in 2022, then surged by 49.44% to $13113.0 in 2023, then decreased by 23.69% to $10007.0 in 2024, then surged by 9375.79% to $948242.0 in 2025.
  • Its Interest Expenses stands at $948242.0 for Q3 2025, versus $6671.0 for Q2 2025 and $10007.0 for Q1 2025.